Nicholas Mitsiades

Professor

University of California, Davis

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Nicholas Mitsiades is a faculty member at the University of California, Davis, specializing in cancer research. His recent work includes studies on neuroendocrine prostate cancer, patient-derived xenograft models, and the impact of socioeconomic factors on racial disparities in prostate cancer. He focuses on the therapeutic potential of BRD4 inhibitors, immunotherapy enhancements, and the mechanisms underlying cancer progression in various populations.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nicholas Mitsiades

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.

Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.

Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma

Inhibition of GATA2 in prostate cancer by a clinically available small molecule

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.

Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.

Collaborators (7)

Aleksandra Rusin

Charles Foulds

Michael Scheurer

Suzanne Fuqua

Patricia Castro

Salma Kaochar

Eric Gustavo Ramírez-Salazar

Make your next move.